Form 4: Mirum Pharmaceuticals CEO Christopher Peetz Exercises Options and Sells Shares
SEC Form 4 Filing
CEO Christopher Peetz exercised stock options and sold shares of Mirum Pharmaceuticals on March 3, 2025, according to a Form 4 filing with the SEC.
Summary
- On March 3, 2025, Christopher Peetz, CEO of Mirum Pharmaceuticals, exercised stock options to acquire 40,000 shares of common stock at a price of $2.936 per share.
- Simultaneously, Peetz sold 19,392 shares at a weighted average price of $46.61 and 20,608 shares at a weighted average price of $47.19.
- Following these transactions, Peetz directly owns 115,920 shares and indirectly owns 208,570 shares through The Peetz Family Trust.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports transactions. The use of a 10b5-1 plan suggests routine activity.
Industry Context
Executive stock sales are common and often pre-planned to diversify personal holdings and comply with insider trading regulations. The use of a 10b5-1 plan suggests the sales were planned in advance.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sale mitigates this risk.
Key Dates
| Date | Description |
|---|---|
| 11/22/2024 | Date of adoption of Rule 10b5-1 Plan |
| 03/03/2025 | Date of transaction: Exercise of stock options and sale of shares |
| 03/04/2025 | Date of Form 4 filing |
| 03/11/2029 | Expiration date of Employee Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.